|Bid||5.14 x 800|
|Ask||8.38 x 2200|
|Day's Range||6.94 - 7.55|
|52 Week Range||6.92 - 13.85|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aridis Pharmaceuticals (ARDS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Attractive stocks have exceptional fundamentals. In the case of Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), there's is a company with strong financial health as well as a excellent growth outlook. Below, I've Read More...
Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
Why a South Bay company thinks it can disrupt a tough antibiotics market — and more in our weekly Health Care Digest.